Cytodyne v. EAS
This article was originally published in The Tan Sheet
Executive Summary
EAS held in contempt by Newark, N.J. federal Judge Dickinson Debevoise Dec. 23 for violating preliminary injunction barring it from disseminating allegedly false, misleading ads for BetaLean HP. Contempt finding resulted from EAS' failure to stop making certain claims, including statements that BetaLean HP's proprietary formula enhances the thermogenic effect of the product's original ephedrine/caffeine combination. EAS has since removed the disputed claims from its Web site and, pursuant to the court's order, posted the following statement, which also must be distributed to firm's distributors, retailers: "A U.S. District Court found that this claim is not true and that the proprietary formula has been found to reduce and inhibit the overall thermogenic effect of the ephedrine and caffeine combination." Argument on Cytodyne's motion to dismiss an EAS countersuit will be Jan. 27 (1"The Tan Sheet" Dec. 9, 2002, p. 8)...
You may also be interested in...
Cytodyne “Before-After” Weight-Loss Photos Subject Of EAS Countersuit
"Before-and-after" photos used in ads for Cytodyne Technologies' Xenadrine weight-loss products are false and misleading, a countersuit filed by Golden, Colo.-based Experimental & Applied Sciences alleges
US WorldMeds’ Eflornithine Gets US FDA Panel Nod For Pediatric Neuroblastoma
In 14-6 vote, advisory committee said use of external control comparison to contextualize single-arm trial data demonstrated efficacy and reliance on preclinical data as confirmatory evidence was justified.
Veru Hopes To Position Enobosarm As Muscle-Protective In Weight-Loss Therapy
A selective androgen receptor modulator also being studied in metastatic breast cancer, enobosarm might offer potential as add-on therapy to GLP-1 agonists prescribed for weight loss, the Miami biotech asserts.